SCHEMBL5848341

SCHEMBL5848341

CC(C)CCC(=O)C(NC(=O)c1ccccc1OCc1ccccc1)N1CCCCc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 3/20 0.42
HCN1 O60741 1/20 0.42
HCN4 Q9Y3Q4 1/20 0.42
FAAH O00519 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.40
CTSK P43235 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 3/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5850500 0.86 TAOK1 (0.46) MEN1KMT2APOLBMAPT
SCHEMBL5848748 0.84 ALDH1A1 (0.48) FAAHCNR2MEN1KMT2AALDH1A1
SCHEMBL5850462 0.84 HCN1 (0.43) SGMS2HCN1HCN4FAAHCNR1
SCHEMBL5848665 0.83 MAPT (0.47) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL5849226 0.79 BRS3 (0.42) SGMS2HCN1HCN4FAAHCNR1
SCHEMBL5848336 0.78 CTSK (0.47) SGMS2HCN1HCN4MEN1KMT2A
SCHEMBL5848555 0.74 GAA (0.43) MEN1KMT2AALDH1A1GAASMN1; SMN2
SCHEMBL5849892 0.73 POLB (0.42) ALDH1A1SMN1; SMN2POLBLMNAMAPT
SCHEMBL5850038 0.70 TAOK1 (0.49) MEN1KMT2ACTSKPOLB
SCHEMBL5850457 0.70 CTSK (0.48) SGMS2HCN1HCN4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7008938-B2 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient NOKIA CORPORATION (FI) 2006-03-07 US disclosed
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. 2005-01-13 US disclosed
US-6809092-B2 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-10-26 US disclosed
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient NOKIA CORPORATION (FI) 2003-08-28 US disclosed
EP-1254898-A1 BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient BACH1, BACE1, CMA1 SGMS2 3111/4885HCN1 2419/4885HCN4 2541/4885
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient BACE1, BACE2, CBS SGMS2 1954/4885HCN1 3282/4885HCN4 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.